Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: ozanezumab, atinumab | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 216 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 4178
Sealed predictions
- RTN4 in dopamine neurons, braak+0.37 (p 0.329) → +0.37 (p 0.323)receipt 4184
Swarm cases
receipt 4184: RTN4 in dopamine neurons, braak
- power
- full sample +0.34 (p 0.170, n 18), 95% CI -0.15 to +0.70. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.35 (p 0.159, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.55 (p 0.018, n 18). not the mix.
- skeptic
- leave-one-out range +0.25 to +0.49, sign flips 0; without severely affected donors +0.34 (p 0.170, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RTN4 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts